Connexion
English

Launched by Dr. Jean-Claude Tardif, Director of the Research Centre Director at the MHI

This major project is the result of a public-private partnership that will help Quebec position itself as a world leader in research through a paradigm shift in the conduct of clinical trials.

JC Tardif

Studies supported by the MHI

68105

COLCOT-T2D

Do you treat patients with diabetes aged 55 and over or are you a patient with diabetes? Participate in this provincial study supported by Diabetes Quebec!

Learn more

68106

MAPLE CHF

A consistent approach to the identification of heart failure patients (HF). Support primary care physicians in screening patients!

Soon available

Project objectives

  1. Facilitate patient participation in clinical studies by creating a bridge between healthcare delivery and research.
  2. Move clinical trials to the patient's home, with virtual exchanges and treatment home delivery.
  3. Create a collaborative platform in OMNIMED to help healthcare professionals, researchers and patients to work together and exchange relevant clinical data.
  4. Clarify consent processes electronically.

“To advance health care, together, we first need to provide patients with simple and effective access to clinical studies that are relevant to their care pathway so that they can contribute in an informed way to improving modern medicine. Quebec has created a powerful collaborative force between patients, their care team, and researchers with this initiative. The health crisis has revealed the importance of clinical data to guide care. As a pioneer in the electronic medical record and in managing millions of Quebecers’ clinical data, Omnimed will make available to patients the tools needed to accelerate clinical research in Quebec.”

- Nicolas Beaudet, Scientific Director at Omnimed

68105

Study of the effects of colchicine and enteric-coated aspirin on cardiovascular events in type 2 diabetic patients

Together, Omnimed and the Montreal Heart Institute (MHI) aim to transform clinical trials on type 2 diabetes and make Quebec a hub for quality care in this sector!

This virtual study, launched in January 2023, is the first of its kind in this provincial program, which is funded by the Instituts de recherche en santé du Canada. No travel necessary. Centre de coordination des essais cliniques de Montréal (MHICC) will onboard the patients and do the follow-ups all virtually. It is possible to participate no matter where you are in Quebec!

  • Patients aged 55 to 80

  • With a diagnosis of type 2 diabetes

  • With no history of cardiovascular disease

For clinicians

We are working to develop new tools and dashboards that will facilitate the clinical follow-up of your diabetic patients. Research is the vehicle for these changes!

  • Generate your list of patients that might be eligible to the study
  • You would like to contact these patients to invite them to participate in the study? We can help you with that! Send us a chat through the EMR or write to us at support@omnimed.com, mention that you wish to involve your patients in the COLCOT-T2D study and we will direct your request.
  • See directly in your patient's file their registration for the research project (in the Programs summary box).

To come

  • Our team is currently working on a project that will allow all patients to give their pre-consent to research. What does that mean? Patients can themselves indicate that they are interested in being contacted for research projects relevant to them.

  • Eventually, you will be able to send mass emails yourself to reach your patients more easily.

For patients

  • Having type 2 diabetes
  • Being between 55 and 80 years of age.

  • Having no know history of cardiovascular disease (i.e. a heart attack, a stroke, or any disease of the heart or arteries for example - if you are not sure, we will validate for you)

You can contact the coordination team of the study directly.
It will be easy, everything will be done virtually, by phone or video!

1-877-587-3389

Back to the list of studies

Omnimed involvement

As a main partner, Omnimed is investing in developing new features that will facilitate follow-ups with patients and adherence to the discovery process. It will also contribute to the dissemination of knowledge by sharing the results of research with healthcare teams through the principles of continuing education, and by promoting the integration of good practices that emerge through assessment, screening and education.

name-8

Patient

Decide on the use of their own data for research and help improve the work tools of many health professionals in Quebec, including their care team

Have the opportunity to be contacted for clinical studies relevant to their condition

Participate in studies from here

Keep their healthcare team informed of their choices and the clinical studies in which they are participating.



Learn more about our privacy policy
name-37

Health professionals

Benefit from clinical tools developed and integrated into the EMR as part of targeted care trajectories in research projects

Obtain dashboards on their patients about targeted health conditions

Access recent clinical content within Omnimed through our targeted collaborations with key opinion leaders (KOL)

Contribute to research in a simple click, through regular follow-ups with patients

Easily educate patients about participating in research projects that contribute to the advancement of health care
name-33

Researchers

Benefit from an electronic medical record that has been designed to facilitate research

Contribute to a new channel of communication between the patient and the researcher

Provide more feedback to patients on the impact of research

Access a network rich in collaborations to advance medicine

Partners

logo-ciusss
cgp-mcgill
CHUM
chuLogo
icone